Rocket Lab's delayed Neutron first flight pushes out a key part of its planned launch capacity. Flight one has moved to 2027, at least 1.5 years later than the previously indicated timing; the lack of clearer guidance is frustrating. The stock could fall 50% if it breaks key support, though that downside is conditional. x.com  x.com  x.com 

Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab's Neutron delay looks like a manufacturing issue, not a flawed design. Rocket Lab says it identified and mitigated dome voids, but this second setback delays launch revenue; first flight could slip to mid-2027 or later if testing finds more issues. Space Systems is about 81% of revenue and backlog is around $2.4B, sustaining the business as Neutron develops. Rocket Lab could still become a megacap over the next decade. x.com 

Rocket Lab shares look set to grind as Neutron's first flight slips, even though the core business is at its strongest. Q2 revenue hit a record $234.1M, up 62%, and backlog rose 137% to $2.356B. But the Q3 guide cuts GAAP gross margin to 29-31% from 36.1%, below the ~37.6% expected, with adjusted EBITDA losses widening to $17-23M on low-margin satellite programs, Mynaric integration and Neutron spending. A Q1 2027 Neutron debut is now the base case, which will disappoint high expectations. x.com 

Rocket Lab's government awards and backlog look priced in, while the costs of Neutron do not. Its space-beta monopoly has ended with SpaceX's listing, and it needs to max out R&D to accelerate Neutron before its maiden flight. A brand-new rocket, a new methalox engine and a new launch site burning more money mean weak earnings the market has apparently not priced. x.com  x.com 

Rocket Lab's Neutron delay adds litigation risk despite continued support for the stock. Spaceflight Now reports a forward-dome manufacturing defect has pushed the debut into 2027, at the worst possible time. Expect a lawsuit with real merit; if recalled correctly, management said Neutron would be ready in mid-2025. x.com 

Rocket Lab's Neutron delay could drag public space stocks down because the space basket usually trades together. Rocket Lab is likely to pull AST SpaceMobile down with it, especially in a bad market. The delay also pushes back a possible AST launch on Neutron, though that launch was not expected and the news is not necessarily bad for AST directly. x.com  x.com  x.com 

Rocket Lab has no reason to climb back above $100 anytime soon without a huge catalyst. Earnings were OK but nothing to rave about, and Neutron was delayed. x.com 

Rocket Lab's existing Space Systems business makes Neutron upside optionality rather than the whole investment case. Space Systems supplied $189.5M, about 81% of Q2's record $234M revenue, alongside Electron launches, defense work, satellite manufacturing and components. Delaying Neutron's first launch to 2027 hurts a major catalyst and raises execution questions, but rushing a rocket failure would be costlier. x.com 

Rocket Lab still looks ridiculously expensive at 29 times forward sales against SpaceX at 22 times, even after a 65% fall. At 22 times, Rocket Lab would be roughly $38, and SpaceX would still be the pick. SpaceX also has better forward guidance; Rocket Lab's negative adjusted EBITDA makes sales multiples the valuation yardstick. x.com  x.com  x.com  x.com